IC
RPRX icon

IEQ Capital’s Royalty Pharma RPRX Stock Holding History

IEQ Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-104,778
Closed -$5.03M – 2159
2026
Q1 		$5.03M Buy
104,778
+81,315
+347% +$3.56M 0.02% 506
2025
Q4 		$907K Sell
23,463
-142,125
-86% -$5.42M ﹤0.01% 1082
2025
Q3 		$5.84M Buy
165,588
+34,728
+27% +$1.26M 0.02% 450
2025
Q2 		$4.71M Buy
130,860
+60,448
+86% +$2M 0.03% 440
2025
Q1 		$2.19M Buy
70,412
+27,597
+64% +$875K 0.02% 564
2024
Q4 		$1.09M Buy
42,815
+7,184
+20% +$190K 0.01% 642
2024
Q3 		$1.01M Sell
35,631
-4,942
-12% -$137K 0.01% 545
2024
Q2 		$1.07M Sell
40,573
-4,995
-11% -$138K 0.01% 463
2024
Q1 		$1.38M Buy
45,568
+6
+0% +$177 0.02% 394
2023
Q4 		$1.28M Sell
45,562
-1,717
-4% -$47.2K 0.02% 372
2023
Q3 		$1.28M Buy
47,279
+167
+0.4% +$4.96K 0.03% 339
2023
Q2 		$1.45M Sell
47,112
-1,095
-2% -$37.1K 0.03% 320
2023
Q1 		$1.74M Buy
48,207
+2,631
+6% +$97.6K 0.04% 279
2022
Q4 		$1.8M Sell
45,576
-190
-0.4% -$7.93K 0.05% 259
2022
Q3 		$1.84M Buy
45,766
+191
+0.4% +$8.16K 0.05% 247
2022
Q2 		$1.92M Sell
45,575
-66
-0.1% -$2.71K 0.06% 212
2022
Q1 		$1.78M Buy
45,641
+29
+0.1% +$1.14K 0.04% 228
2021
Q4 		$1.82M Sell
45,612
-1,415
-3% -$55K 0.04% 213
2021
Q3 		$1.7M Buy
47,027
+1,466
+3% +$57K 0.05% 211
2021
Q2 		$1.87M Sell
45,561
-18
-0% -$766 0.05% 184
2021
Q1 		$1.99M Buy
45,579
+29
+0.1% +$1.38K 0.08% 137
2020
Q4 		$2.28M Buy
+45,550
New +$1.93M 0.1% 117

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IEQ Capital's RPRX Position: Q2 2026 in Review

IEQ Capital sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 104,778 shares — an estimated $5.03M sold.

IEQ Capital first reported a position in RPRX in Q4 2020 and held it in 22 quarters. The position peaked at $5.84M in Q3 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • IEQ Capital reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • IEQ Capital sold 104,778 Royalty Pharma shares in Q2 2026, an estimated $5.03M.
  • IEQ Capital first reported a position in Royalty Pharma in Q4 2020 and held it in 22 quarters.
  • IEQ Capital's Royalty Pharma position peaked at $5.84M in Q3 2025.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on IEQ Capital's 13F filing for Q2 2026, filed 11 Aug 2026.